← Oncology Approval Tracker

FDA DECISION ·

Besremi

ropeginterferon alfa-2b-njft · PharmaEssentia

FDA approvalNew therapyPolycythemia vera
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with polycythemia vera.

LAMPGEN ANALYSIS

Why it matters

The action adds a long-acting interferon option for a chronic myeloproliferative neoplasm.

What research teams should watch

Track hematocrit and phlebotomy timing across visits and reconcile dose titration.

PRIMARY RECORDS

Sources